Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System

There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were h...

Descripción completa

Detalles Bibliográficos
Autores principales: Dryden-Peterson, Scott, Kim, Andy, Joyce, Mary-Ruth, Johnson, Jennifer A, Kim, Arthur Y, Baden, Lindsey R, Woolley, Ann E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620388/
https://www.ncbi.nlm.nih.gov/pubmed/36438619
http://dx.doi.org/10.1093/ofid/ofac565
_version_ 1784821328858054656
author Dryden-Peterson, Scott
Kim, Andy
Joyce, Mary-Ruth
Johnson, Jennifer A
Kim, Arthur Y
Baden, Lindsey R
Woolley, Ann E
author_facet Dryden-Peterson, Scott
Kim, Andy
Joyce, Mary-Ruth
Johnson, Jennifer A
Kim, Arthur Y
Baden, Lindsey R
Woolley, Ann E
author_sort Dryden-Peterson, Scott
collection PubMed
description There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).
format Online
Article
Text
id pubmed-9620388
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96203882022-11-04 Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System Dryden-Peterson, Scott Kim, Andy Joyce, Mary-Ruth Johnson, Jennifer A Kim, Arthur Y Baden, Lindsey R Woolley, Ann E Open Forum Infect Dis Brief Report There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14). Oxford University Press 2022-10-27 /pmc/articles/PMC9620388/ /pubmed/36438619 http://dx.doi.org/10.1093/ofid/ofac565 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Dryden-Peterson, Scott
Kim, Andy
Joyce, Mary-Ruth
Johnson, Jennifer A
Kim, Arthur Y
Baden, Lindsey R
Woolley, Ann E
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
title Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
title_full Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
title_fullStr Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
title_full_unstemmed Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
title_short Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
title_sort bebtelovimab for high-risk outpatients with early covid-19 in a large us health system
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620388/
https://www.ncbi.nlm.nih.gov/pubmed/36438619
http://dx.doi.org/10.1093/ofid/ofac565
work_keys_str_mv AT drydenpetersonscott bebtelovimabforhighriskoutpatientswithearlycovid19inalargeushealthsystem
AT kimandy bebtelovimabforhighriskoutpatientswithearlycovid19inalargeushealthsystem
AT joycemaryruth bebtelovimabforhighriskoutpatientswithearlycovid19inalargeushealthsystem
AT johnsonjennifera bebtelovimabforhighriskoutpatientswithearlycovid19inalargeushealthsystem
AT kimarthury bebtelovimabforhighriskoutpatientswithearlycovid19inalargeushealthsystem
AT badenlindseyr bebtelovimabforhighriskoutpatientswithearlycovid19inalargeushealthsystem
AT woolleyanne bebtelovimabforhighriskoutpatientswithearlycovid19inalargeushealthsystem

Ejemplares similares